-1753359861743.webp&w=3840&q=75)
2025 NOSCM | Optimal Therapy for Early Stage Triple Negative Breast Cancer
Overview
Dr. Hope Rugo emphasized neoadjuvant therapy for TNBC and the role of pembrolizumab.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Hope S. Rugo, MD, FASCO
Date of Release
July 24th, 2025
-1756043706259.webp&w=3840&q=75)
-1756043607111.webp&w=3840&q=75)